0.07
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rhythm Biosciences
Its shares trade on ASX under the ticker RHY.AX. It has been listed since 7 December 2017. In the fiscal year to 30 June 2026, it reported revenue of A$85,339 and a net loss of A$5.9m. At that date it held total assets of A$4.8m and shareholders' equity of A$3.6m.
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The firm is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company’s ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 7 Dec 2017
- Website
- rhythmbio.com ↗
Leadership
Pay as last reported
- Mr. Gavin Fox-SmithChairman of the Board, since 2024
- Mr. David AtkinsChief Executive Officer, Managing Director, Director, since 2024
- Mr. Todd PerkinsonChief Financial Officer
- Ms. Andrea SteeleGeneral Counsel, Joint Company Secretary
- Mr. Guy CarisbrookeFinancial Controller
- Ms. Elena DeakChief Commercial Officer
- Mr. James BarrieJoint Company Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rhythm Biosciences Ltd. develops ColoSTAT, a blood-based cancer test for colorectal cancer screening in Australia.
- ColoSTAT targets adults aged 40 to 85 at average risk for colorectal cancer in domestic and international markets.
- Rhythm Biosciences focuses on medical diagnostics technologies for early cancer detection in the Health Care sector.
Weaknesses
- Rhythm Biosciences Ltd. has limited commercialization of ColoSTAT in international markets beyond Australia.
- The company relies on a single product, ColoSTAT, for its medical diagnostics technology development.
- Rhythm Biosciences operates in the competitive Health Care sector with established diagnostic companies.
Opportunities
- ColoSTAT's blood-based test technology offers a non-invasive alternative for colorectal cancer screening in the Health Care industry.
- The global market for colorectal cancer screening is expanding, creating opportunities for Rhythm Biosciences Ltd.
- Rhythm Biosciences can expand ColoSTAT's use to other cancer types or markets with further development.
Threats
- Rhythm Biosciences faces competition from established diagnostic companies in the Health Care sector.
- The company's reliance on ColoSTAT as a single product poses a risk if the technology fails to gain market acceptance.
- Regulatory approval delays could hinder the commercialization of ColoSTAT in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.